- Anti-CD20 therapy in inflammatory rheumatic diseasesPublication without faculty affiliation
- Harmful inflammation in multiple sclerosis patients is effectively suppressed by administration of anti-CD20 biologics modulating mature B cells. Does the route of their administration matters?2023 | Faculty of Medicine in Hradec Králové
- HPMA copolymer conjugates with reduced anti-CD20 antibody for cell-specific drug targeting. I. Synthesis and in vitro evaluation of binding efficacy and cytostatic activity2009 | First Faculty of Medicine
- B cells as an integral part of harmful inflammation in multiple sclerosis and affecting them with anti-CD20 therapy2017 | Faculty of Medicine in Hradec Králové
- Anti-CD20 (rituximab) treatment for atopic eczema2008 | Second Faculty of Medicine
- The induction of molecular genetic conversion in bone marrow (BM) in Patients with indolent Lymphomas Treated by Mnoclonal Antibody anti-CD20 (MABTHERA)Publication without faculty affiliation
- Ofatumumab - new and different monoclonal anti-CD20 antibody in the treatment of multiple sclerosis2021 | Second Faculty of Medicine
- Inhibition of PIM Kinases in DLBCL Targets MYC Transcriptional Program and Augments the Efficacy of Anti-CD20 Antibodies2021 | First Faculty of Medicine
- Implications of rituximab pharmacokinetic and pharmacodynamic alterations in various immune-mediated glomerulopathies and potential anti-CD20 therapy alternatives2022 | First Faculty of Medicine
- Biological drugs in hematooncology2012 | First Faculty of Medicine
- Radioimmunotherapy with 90Y-radiolabelled anti-CD20 monoclonal antibody in patients with B-cell non-Hodgkin´s lymphoma +3Publication without faculty affiliation
- Anti-Lymphoma Efficacy Comparison of Anti-CD20 Monoclonal Antibody-Targeted and Non-Targeted Star-Shaped Polymer-Prodrug Conjugates2015 | First Faculty of Medicine
- Radioimmunotherapy with 90Y-radiolabelled anti-CD20 Monoclan Antibody in Patients with B-cell non-Hodgkin´s Lymphoma, Nuclear Medicine as a Part of the Oncology Team2005 | Faculty of Medicine in Hradec Králové
- Targeted treatment for chronic lymphocytic leukemia: clinical potential of obinutuzumab2014 | Faculty of Medicine in Hradec Králové
- The Clinical Outcome of Patients with B-cell Lymphoproliferative Disease (B-LPD) Seems to Be Improved by the Success in Induction of Polymerase Chain Reaction (PCR) Negativity Achieved by High Dose Therapy with Autologous Stem Cell TransplantPublication without faculty affiliation
- Ofatumumab treatment of fludarabine and alemtuzumab refractory patients2012 | Faculty of Medicine in Hradec Králové
- Ofatumumab retreatment and maintenance in fludarabine-refractory chronic lymphocytic leukaemia patients2015 | Publication without faculty affiliation
- Ofatumumab retreatment and maintenance in fludarabine-refractory chronic lymphocytic leukaemia patients2015 | Faculty of Medicine in Hradec Králové
- Monoclonal Antibodies in the Treatment of Chronic Lymphocytic Leukemia in 20152015 | First Faculty of Medicine
- The role of rituximab maintenance in elderly patients with mantle cell lymphoma in first remission - single centre experience2015 | Faculty of Medicine in Pilsen
- Plasmapheresis and intravenous immunoglobulin in the treatment and prevention of antibody mediated rejection2010 | Central Library of Charles University
- New autoimmune diseases after cord blood transplantation: a retrospective study of EUROCORD and the Autoimmune Disease Working Party of the European Group for Blood and Marrow Transplantation2013 | Second Faculty of Medicine
- Ofatumumab2011 | Faculty of Medicine in Hradec Králové
- Maintenance treatment with rituximab in nonhodgkin's lymphoma2012 | Faculty of Medicine in Hradec Králové
- Prognostic significance of FCGR2B expression for the response of DLBCL patients to rituximab or obinutuzumab treatment2021 | First Faculty of Medicine
- Ofatumumab - a new high-efficacy treatment for relapsing forms of multiple sclerosis2021 | Faculty of Medicine in Hradec Králové
- Ofatumumab - a highly effective therapy for relapsing-remitting multiple sclerosis available in the first line2022 | Faculty of Medicine in Hradec Králové